Advertisement
RESEARCH ARTICLE
Glycogen synthase kinase-3 inhibition attenuates fibroblast activation and development of fibrosis following renal ischemia-reperfusion in mice
Shailendra P. Singh, Shixin Tao, Timothy A. Fields, Sydney Webb, Raymond C. Harris, Reena Rao
Disease Models & Mechanisms 2015 8: 931-940; doi: 10.1242/dmm.020511

ABSTRACT

Glycogen synthase kinase-3β (GSK3β) is a serine/threonine protein kinase that plays an important role in renal tubular injury and regeneration in acute kidney injury. However, its role in the development of renal fibrosis, often a long-term consequence of acute kidney injury, is unknown. Using a mouse model of renal fibrosis induced by ischemia-reperfusion injury, we demonstrate increased GSK3β expression and activity in fibrotic kidneys, and its presence in myofibroblasts in addition to tubular epithelial cells. Pharmacological inhibition of GSK3 using TDZD-8 starting before or after ischemia-reperfusion significantly suppressed renal fibrosis by reducing the myofibroblast population, collagen-1 and fibronectin deposition, inflammatory cytokines, and macrophage infiltration. GSK3 inhibition in vivo reduced TGF-β1, SMAD3 activation and plasminogen activator inhibitor-1 levels. Consistently in vitro, TGF-β1 treatment increased GSK3β expression and GSK3 inhibition abolished TGF-β1-induced SMAD3 activation and α-smooth muscle actin (α-SMA) expression in cultured renal fibroblasts. Importantly, overexpression of constitutively active GSK3β stimulated α-SMA expression even in the absence of TGF-β1 treatment. These results suggest that TGF-β regulates GSK3β, which in turn is important for TGF-β–SMAD3 signaling and fibroblast-to-myofibroblast differentiation. Overall, these studies demonstrate that GSK3 could promote renal fibrosis by activation of TGF-β signaling and the use of GSK3 inhibitors might represent a novel therapeutic approach for progressive renal fibrosis that develops as a consequence of acute kidney injury.

INTRODUCTION

Renal fibrosis is a classic outcome of multiple forms of chronic kidney disease. It is characterized by excessive extracellular matrix (ECM) remodeling, which results in progressive loss of renal function and often leads to end-stage renal disease (Chuang et al., 2013). Renal fibrosis can also develop as a consequence of maladaptive repair after acute kidney injury (AKI) (Bonventre and Yang, 2011; Venkatachalam et al., 2010). For instance, AKI caused by ischemia-reperfusion (I/R) can result in inadequate tubular regeneration, chronic inflammation, macrophage infiltration and fibroblast activation, leading to excessive ECM deposition and fibrosis (Bonventre and Yang, 2011; Jang et al., 2014; Kim and Padanilam, 2015; Yang et al., 2010; Zhou et al., 2014).

The glycogen synthase kinase-3 (GSK3) family of protein kinases consists of GSK3α and GSK3β isoforms, and plays an important role in injury and repair of renal tubular epithelial cells in AKI. A proapoptotic role for the GSK3β isoform was demonstrated in experimental AKI using gene silencing in vitro (Wang et al., 2010), or gene deletion in vivo (Howard et al., 2012). Moreover, pharmacological inhibition using isoform non-selective GSK3 inhibitors reduced apoptosis and renal tubular injury in AKI induced by lipopolysaccharides, I/R and nephrotoxins (Bao et al., 2012; Howard et al., 2012; Plotnikov et al., 2013; Wang et al., 2009, 2010). In previous studies we demonstrated that renal-proximal-tubule-specific gene deletion of GSK3β could accelerate renal tubular repair after HgCl2-induced AKI in mice (Howard et al., 2012). We also showed that GSK3 inhibition using TDZD-8, 48 h after a nephrotoxic insult, can significantly improve renal tubular repair by increasing pro-proliferative cyclin-D1, c-myc and β-catenin (Howard et al., 2012). These results were subsequently affirmed by studies using LiCl in cisplatin and I/R injury models of AKI (Bao et al., 2014). Thus, inhibition of GSK3 could be a viable strategy for the treatment of AKI. However, it is unclear whether GSK3β is expressed in renal myofibroblasts, the major producers of ECM, or whether GSK3β is involved in the development of renal fibrosis.

GSK3 regulates multiple cell signaling pathways by suppressing accumulation or transcriptional activity of key mediators of these pathways in the absence of ligands or activators (Beurel et al., 2015). Some of these cell-signaling pathways, including TGF-β, Wnt, sonic hedgehog, EGFR and BMP signaling, are important for fibrosis (Chuang et al., 2013; LeBleu et al., 2013). Hence, it could be hypothesized that inhibition of GSK3 would mimic activation of these pro-fibrotic signaling pathways, leading to fibrosis. However, the role of GSK3β in fibrosis seems to be cell- and context-dependent. For instance, in vitro, GSK3 inhibition can cause epithelial-to-mesenchymal transition (EMT) in renal tubular epithelial cells by activation of TGF-β1 and an increase in Snail levels (Lan et al., 2014; Noh et al., 2012), whereas, in cultured glomerular mesangial cells, GSK3 inhibition reduces TGF-β1 signaling and fibronectin accumulation (Ho et al., 2012). Moreover, GSK3 inhibition can reduce inflammation, an essential prelude to renal fibrosis (Martin et al., 2005; Wang et al., 2011). Given this complexity and our previous observations that inhibition of GSK3 reduces injury and accelerates repair in the acute setting of AKI, its effect on renal fibrosis, a long-term outcome of AKI, remains to be defined.

In the current studies we examined the role of GSK3β in the development of renal fibrosis and tested the effect of pharmacological inhibition of GSK3 in an I/R-induced mouse model of renal fibrosis. The results of these studies are presented.

TRANSLATIONAL IMPACT

Clinical issue

Chronic kidney disease affects about 10% of the population and is a major cause of death in the United States and other developed countries. Renal fibrosis – a classic outcome of many forms of chronic kidney disease – is characterized by excessive extracellular matrix (ECM) remodeling, which results in progressive loss of renal function and often leads to end-stage renal disease. Renal fibrosis can also develop as a consequence of maladaptive repair after acute kidney injury (AKI). For instance, AKI caused by ischemia-reperfusion (I/R) can result in inadequate regeneration, chronic inflammation, macrophage infiltration and fibroblast activation, leading to excessive ECM deposition and, in the long-term, renal fibrosis. Glycogen synthase kinase-3β (GSK3β) is a serine/threonine protein kinase that is known to play an important role in injury and regeneration of the renal tubules in AKI. Although inhibition of GSK3β can reduce injury and accelerate repair, its role in the development of renal fibrosis is currently unknown.

Results

Here, the authors use a mouse model of renal fibrosis induced by I/R injury to demonstrate that GSK3β expression and activity are increased in fibrotic kidneys and to show that GSK3β is present in myofibroblasts, the major producers of ECM. The authors report that pharmacological inhibition of GSK3 using TDZD-8 (a non-selective inhibitor that acts on both GSK3α and GSK3β) starting before or after I/R injury suppresses renal fibrosis by reducing the myofibroblast population, collagen-1 and fibronectin deposition, the expression of inflammatory cytokines, and macrophage infiltration. GSK3 inhibition in vivo reduces TGF-β1 mRNA levels, SMAD3 activation, and plasminogen activator inhibitor-1 levels. Consistently, TGF-β1 treatment increases GSK3β expression and GSK3 inhibition abolishes TGF-β1-induced SMAD3 activation and α-SMA expression in cultured renal fibroblasts. Importantly, the authors also show that overexpression of constitutively active GSK3β stimulates α-SMA expression even in the absence of TGF-β1 treatment.

Implications and future directions

These results indicate that, after I/R injury, TGF-β regulates renal GSK3β, which in turn is important for TGF-β–SMAD3 signaling and fibroblast-to-myofibroblast differentiation. Thus, GSK3 could promote renal fibrosis after AKI by activation of TGF-β signaling. The finding that GSK3 inhibition, starting even after AKI has occurred, can reduce fibrosis is important because a large percentage of AKI cases are detected only after fibrosis has begun to develop. The use of GSK3 inhibitors might, therefore, represent a novel approach for the treatment of the progressive renal fibrosis that develops as a consequence of AKI.

RESULTS

Renal GSK3β expression increases following I/R

To determine the role of GSK3β in the development of renal fibrosis, we first examined its expression and activation in the kidneys of mice subjected to bilateral renal I/R. A time-course analysis of renal GSK3β expression following I/R showed a significant increase in total GSK3β levels by day-2, which at day-12 remained twofold higher than at day-0 (Fig. 1A,B). The serine-9 phosphorylated (inactive) form of GSK3β (pGSK3β) increased significantly by day-2, following which it returned to baseline levels. The ratio of pGSK3β to GSK3β did not change significantly on day-2 and was further reduced on day-3 and -12, suggesting an increase in GSK3β activity (Fig. 1A,B). Expression levels of renal α-smooth muscle actin (α-SMA), a marker of myofibroblasts, also increased, starting on day-2 following I/R (Fig. 1A). Immunofluorescence (IF) staining demonstrated that GSK3β colocalizes with α-SMA in day-2 as well as day-12 I/R kidneys (Fig. 1C). The day-12 I/R kidneys were fibrotic as determined by Masson's-trichrome staining and Sirius-red staining (supplementary material Fig. S1A). GSK3β expression was detected in proximal tubules and, to a lower extent, in collecting ducts, but not thick ascending limbs (supplementary material Fig. S1B). Unlike proximal tubules and myofibroblasts, macrophages (stained by the marker F4/80) in day-12 I/R kidneys rarely stained for GSK3β (supplementary material Fig. S1C).

Fig. 1.
Fig. 1.

Increased GSK3β expression after renal I/R. (A) Western blot analysis and (B) quantitation of band density show increased GSK3β protein levels and reduced inactive pGSK3β-serine-9/GSK3β ratio and increased α-SMA in kidneys after I/R. *P<0.05, **P<0.01 compared to day-0. (C,D) GSK3β (green) and α-SMA (red) co-staining shows that GSK3β is expressed in renal myofibroblasts on (C) day-2 and (D) day-12 after I/R. Scale bars: 25 µm. (E) In rat renal fibroblast-NRK-49F cells, TGF-β1 treatment for 48 h dose-dependently increased GSK3β and pGSK3β levels. (F) Relative band densities of total GSK3β and pGSK3β/GSK3β ratio. **P<0.01, compared to 0 ng/ml TGF-β1 treatment. (G) GSK3β colocalizes with α-SMA in NRK-49F cells. Scale bars: 25 µm. n=6 mice/group for immunoblotting and n=4 mice/group for immunostaining.

To determine whether TGF-β1, a known stimulator of fibroblast-to-myofibroblasts differentiation, can stimulate GSK3β expression, immortalized rat fibroblasts (NRK-49F cells) were treated with TGF-β1. Treatment with TGF-β1 dose-dependently increased GSK3β as well as α-SMA. GSK3β expression doubled at a dose of 2 ng/ml of TGF-β1 and colocalized with α-SMA in myofibroblasts (Fig. 1E-G), whereas the ratio of pGSK3β to GSK3β remained unchanged (Fig. 1E,F). These results demonstrate for the first time increased and sustained GSK3β expression in fibrotic kidneys following I/R or following TGF-β1 treatment in vitro, and its association with myofibroblasts.

Inhibition of GSK3 attenuates development of renal fibrosis after I/R

To determine the role of GSK3 activity in I/R-induced renal fibrosis, we examined the effect of TDZD-8 (TDZD) (Martinez et al., 2002), a highly specific ATP non-competitive inhibitor of GSK3 that we and others have effectively used in mice (Howard et al., 2012; Tao et al., 2015; Wang et al., 2010). Because GSK3β expression increased by day-2 (Fig. 1A), TDZD treatment [1 mg/kg body weight (BWt)] was started on day-2 after I/R in one group of mice (TDZD-Post) and, in a second group, 1 h before I/R (TDZD-Pre) (Fig. 2A). All mice were sacrificed on day-12 after I/R. TDZD treatment did not affect renal GSK3β levels, but significantly increased pGSK3β and pGSK3β/GSK3β levels when compared to vehicle-treated I/R kidneys, suggesting GSK3β inhibition (Fig. 2B,C). As illustrated by trichrome and Sirius-red staining, the TDZD-Pre and TDZD-Post, I/R groups showed a striking reduction in fibrosis compared to the vehicle-treated I/R group (Fig. 2D,E).

Fig. 2.
Fig. 2.

Treatment with TDZD, a GSK3 inhibitor, reduced fibrosis following I/R. (A) Scheme of experimental design. Treatment with TDZD (1 mg/kg BWt), starting 1 hour before I/R (TDZD-Pre) and 2 days after I/R (TDZD-Post). (B) Western blot analysis and (C) densitometry shows increased pGSK3β/GSK3β ratios in TDZD-treated kidneys. (D) Masson's trichrome-, Picro-sirius red- and H&E-stained kidney sections show reduced injury and fibrosis in the TDZD-Pre and TDZD-Post treatment groups 12 days after I/R. (E) Fibrosis score based on Masson's trichrome staining. (F) Blood urea nitrogen (BUN) levels. *P<0.05, **P<0.01, ***P<0.001 compared to vehicle-treated I/R group, n=6 mice/group. Scale bars: 50 µm. All tissue samples were from day-12 after I/R.

Dilated tubules and tubular atrophy were observed in the vehicle-treated I/R group by H&E staining (Fig. 2D), whereas the TDZD-Pre and TDZD-Post treatment groups showed minimal injury. Following I/R, blood urea nitrogen (BUN) levels in the TDZD-Pre treatment group never increased to the high levels as in the vehicle treated group (Fig. 2F). Similarly in the TDZD-Post treatment group, BUN levels reduced significantly as early as 24 h after initiation of treatment (day-3) and decreased to TDZD-Pre treatment levels by day-12. These results indicate that GSK3 inhibition not only preserves renal function in AKI, but TDZD treatment, either pre- or post-I/R, can reduce fibrosis.

TDZD treatment inhibits renal ECM deposition and reduces the myofibroblast population

To determine the effect of GSK3 inhibition on ECM deposition, we measured expression levels of collagen-1 and fibronectin, major matrix components. Because active myofibroblasts are a major source of collagen and fibronectin, we also determined the myofibroblast population in the kidneys by measuring α-SMA expression. Immunostaining for fibronectin, collagen-1 and α-SMA was higher in vehicle-treated I/R kidneys compared to sham kidneys, and TDZD treatment reduced their expression (Fig. 3A). Western blot analysis confirmed these results and showed that, compared to TDZD-Pre, the TDZD-Post treatment group had significantly lower levels of collagen-1, fibronectin and α-SMA (Fig. 3B, supplementary material Fig. S2). Fibronectin, collagen-a1, collagen-3a1 and α-SMA mRNA levels were also increased in vehicle-treated I/R kidneys compared to sham and significantly reduced in TDZD treatment groups (Fig. 3C-F), although no significant difference was observed in mRNA levels between the TDZD-Pre and TDZD-Post treatment groups. These results suggest that inhibition of GSK3 activity can reduce the myofibroblast population and ECM deposition following I/R-injury-induced fibrosis.

Fig. 3.
Fig. 3.

GSK3 inhibition reduced ECM deposition following I/R. (A) Immunostaining and (B) western blot for fibronectin, collagen-1 and α-SMA show reduced levels in the TDZD-Pre and TDZD-Post treatment groups. (C) Quantitative RT-PCR to determine mRNA levels of fibronectin, (D) collagen-a1, (E) collagen 3a1 and (F) α-SMA (fold change, relative to β-actin). **P<0.01, ***P<0.001 compared to vehicle-treated I/R group, n=6 mice/group. Scale bars: 50 µm.

GSK3 inhibition reduced proinflammatory factors and macrophage infiltration

Fibroblast activation can be stimulated by pro-inflammatory cytokines, chemokines and growth factors secreted by damaged epithelial cells, myofibroblasts and infiltrating cells that further enhance tissue fibrosis. We found significant upregulation of mRNA encoding the cytokines TNF-α, IL-6 and IL-1β in vehicle-treated I/R kidneys, compared to sham (Fig. 4A-C). mRNA levels of ICAM-1, a myofibroblast-expressed mediator for interaction with infiltrating leukocytes, were also increased in vehicle-treated I/R kidneys (Fig. 4D). Similarly, monocyte chemoattractants CCL-2 (Furuichi et al., 2009) and CCL-3 (Correa-Costa et al., 2014) were significantly increased in vehicle-treated I/R kidneys (Fig. 4E,F), accompanied by increased macrophage infiltration determined by immunostaining for F4/80 (Fig. 4G). These proinflammatory factors and macrophage infiltration were significantly reduced in the TDZD-Pre and TDZD-Post treatment groups. These results suggest that GSK3 activity could contribute to macrophage infiltration and the production of proinflammatory cytokines in I/R-induced fibrosis.

Fig. 4.
Fig. 4.

GSK3 inhibition reduced pro-inflammatory cytokines and macrophage infiltration following I/R. mRNA levels of (A) TNF-α, (B) IL-6, (C) IL-1β, (D) ICAM-1, (E) CCL-2 and (F) CCL-3 (fold change, relative to β-actin) are lower in TDZD-treated than vehicle-treated I/R kidneys. (G) F4/80 staining shows reduced macrophage infiltration in TDZD-treated compared to vehicle-treated I/R kidneys. **P<0.01, ***P<0.001 compared to vehicle-treated I/R group, n=6 mice/group. Scale bars: 50 µm.

GSK3 inhibition blocks TGF-β signaling but increases β-catenin in epithelial cells

TGF-β signaling plays a crucial role in the development of renal fibrosis. Hence, we examined the effect of TDZD treatment on canonical TGF-β signaling. TGF-β1 mRNA levels were 60% higher in the vehicle-treated I/R group compared to sham (Fig. 5A), with a corresponding increase in TGF-β signaling, suggested by increased pERK and pSMAD3 levels (Fig. 5B,C). IF staining demonstrated pSMAD3 expression in GSK3β-expressing cells (Fig. 5D). In TDZD-Pre and TDZD-Post I/R kidneys, TGF-β1 mRNA, pERK and pSMAD levels were significantly reduced compared to vehicle-treated I/R kidneys (Fig. 5A-C). mRNA levels of TGF-β receptor 1 and 2, and CTGF were unchanged in the TDZD treatment groups compared to vehicle treatment group (data not shown). PAI-1, an inhibitor of collagen degradation, is encoded by an important gene that is upregulated by TGF-β signaling (Ma and Fogo, 2009; Samarakoon et al., 2012). In vehicle-treated I/R kidneys, PAI-1 mRNA levels were threefold higher compared to sham, and TDZD treatment significantly reduced PAI-1 mRNA levels (Fig. 5E).

Fig. 5.
Fig. 5.

GSK3 inhibition reduced TGF-β signaling after I/R. (A) Quantitative RT-PCR shows reduced TGF-β1 mRNA in TDZD-treated compared with vehicle-treated I/R kidneys (fold change, relative to β-actin). (B) Western blot analysis for pSMAD3, SMAD3, pERK1/2 and ERK1/2, and (C) pSMAD3/SMAD3 ratio based on relative band density. (D) Immunostaining for pSMAD3 (red) and GSK3β (green). (E) Quantitative RT-PCR for PAI-1. (F) Western blot analysis shows increased β-catenin levels in TDZD-treated mouse kidney compared to sham- or vehicle-treated kidneys. (G) Immunostaining for β-catenin (red), LTA (green) or α-SMA (green). *P<0.5, **P<0.01, ***P<0.001 compared to vehicle treated I/R group, n=6 mice/group. Scale bars: 25 µm.

Canonical Wnt signaling regulates expression of multiple pro-inflammatory and pro-fibrotic factors (DiRocco et al., 2013). We examined β-catenin, an important component of Wnt signaling, to determine whether TDZD treatment increased its stabilization. Indeed, in TDZD-Pre and TDZD-Post I/R kidneys, β-catenin protein levels were significantly higher than in sham- or vehicle-treated I/R kidneys (Fig. 5F, supplementary material Fig. S3). However, β-catenin expression in TDZD-Pre and TDZD-Post I/R kidneys could be detected only in renal tubules, including Lotus tetragonolobus agglutinin (LTA)-staining proximal tubules (Fig. 5G), but not in the few α-SMA expressing myofibroblasts (Fig. 5G). These results suggest that inhibition of GSK3 suppressed renal fibrosis following I/R by inhibiting TGF-β signaling and not β-catenin-dependent mechanisms.

GSK3 is crucial for TGF-β-induced fibroblast-to-myofibroblast differentiation in vitro

To further determine the role of GSK3 in myofibroblasts, we tested the effect of the GSK3 inhibitors TDZD and SB216763 (a small-molecule inhibitor of GSK3) on TGF-β1-induced α-SMA expression in NRK-49F cells. Pre-treatment with SB216763 (Fig. 6A,C) or TDZD (Fig. 6B,D) significantly reduced α-SMA expression in a dose-dependent fashion. The GSK3 inhibitors also reduced TGF-β1-induced pSMAD3 levels (Fig. 6A,B). To further determine whether an increase in GSK3β in renal fibroblasts can stimulate α-SMA expression, we overexpressed constitutively active GSK3β (AdGSK3β-CA, serine 9-alanine mutant) or control GFP (AdGFP) in NRK-49F cells. After 48 h, GSK3β expression increased in the AdGSK3β-CA transduced cells, accompanied by an increase in α-SMA expression and decrease in β-catenin levels (Fig. 6E,F). These studies demonstrate that GSK3β plays a crucial role in TGF-β signaling and fibroblast activation.

Fig. 6.
Fig. 6.

GSK3 activity is critical for TGF-β1-induced fibroblast activation. Inhibition of GSK3 using (A) SB216763 (SB) or (B) TDZD dose-dependently reduced α-SMA expression and pSMAD3 levels in NRK-49F cells treated with TGF-β1 for 48 h. (C,D) Quantitation of relative band density for α-SMA. (E) Overexpression of constitutively active GSK3β-serine 9-alanine (GSK3β-CA) in NRK-49F cells increases α-SMA but reduces β-catenin compared to cells overexpressing GFP (control). (F) Quantitation of relative band density. *P<0.5, **P<0.01, ***P<0.001 compared to control, n=4.

DISCUSSION

Renal fibrosis is characterized by activation and proliferation of fibroblasts, which continually produce and deposit ECM proteins, leading to progressive fibrosis. Herein we demonstrate that GSK3β is expressed in myofibroblasts, and GSK3β expression and activity are increased in mouse kidneys following I/R and in cultured fibroblasts following TGF-β1 treatment. Pharmacological inhibition of GSK3 using TDZD significantly reduced pro-inflammatory and pro-fibrotic cytokines, macrophage infiltration and ECM deposition, thereby reducing fibrosis. GSK3 inhibition reduced the myofibroblast population in vivo and fibroblast-to-myofibroblast differentiation in vitro by a TGF-β–SMAD signaling-dependent mechanism. Thus, GSK3β plays a pro-fibrotic role in the kidney following I/R, and its inhibition, even after the injury has occurred, could prevent the future development of fibrosis.

GSK3β is expressed in proximal tubules (Nørregaard et al., 2015), and increased GSK3β has been detected in renal tubules of human chronic renal allograft dysfunction tissue by immunohistochemical staining (Gong et al., 2008; Yan et al., 2012). In the current study we found a time-dependent and sustained increase in GSK3β expression and activity following I/R in mouse kidneys. Importantly, and unlike the previous studies, GSK3β expression was detected in α-SMA-expressing myofibroblasts, as early as day-2 following I/R. Moreover, increased GSK3β expression could be linked to fibroblast activation because overexpression of constitutively active GSK3β (serine 21 to alanine mutation) by itself led to an increase in α-SMA expression similar to the effect of TGF-β1 treatment in NRK-49F cells.

Fibroblast activation/differentiation into myofibroblasts, which produce large amounts of ECM components, is a key step in the development of fibrosis (Kalluri and Zeisberg, 2006; LeBleu et al., 2013; Strutz and Zeisberg, 2006). In the vehicle-treated I/R kidneys, we found a large population of myofibroblasts, which was significantly reduced by TDZD treatment. Fibroblasts can be activated by paracrine and autocrine factors, including pro-inflammatory and pro-fibrotic cytokines and chemokines produced by injured tubular epithelial cells, macrophages and myofibroblasts themselves (Grande and Lopez-Novoa, 2009; Kendall and Feghali-Bostwick, 2014). In I/R kidneys, a significant increase in IL-6, IL-1β, TNFα, TGF-β1, macrophage chemoattractants and infiltration of macrophages was found, which were abolished by TDZD treatment. These results are consistent with a pro-inflammatory role for GSK3 (Dugo et al., 2007; Gong et al., 2008; Martin et al., 2005) and suggest that suppressed production of one or more of these cytokines/chemokines could result in reduced fibroblast activation in the TDZD-treated mice.

The chemokine TGF-β, which promotes fibroblast activation, proliferation, migration and ECM synthesis, is a critical mediator of fibrosis (Kramann et al., 2013; Zarjou and Agarwal, 2012). Canonical TGF-β signaling involves binding of TGF-β to its receptors and activation of SMAD3, which, together with SMAD4, regulates the expression of pro-fibrogenic genes (Farris and Colvin, 2012). The role of GSK3 in TGF-β signaling is controversial. In in vitro studies, GSK3 inhibition by pharmacological inhibitors or activation of Wnt signaling attenuated TGF-β1-mediated ECM accumulation in cultured renal glomerular mesenchymal cells, lung, and gingival and skin fibroblasts (Bahammam et al., 2013; Ho et al., 2012; Liu et al., 2012). Similarly, in cultured human renal tubular epithelial cells and corneal fibroblasts, GSK3 inhibition reduced TGF-β1-induced SMAD3 activity (Choi et al., 2011; Zhang et al., 2007). On the other hand, TGF-β inhibits GSK3β via ERK-MAPK in hepatocellular carcinoma (Ding et al., 2005) and cultured peritoneal mesothelial cells (Jang et al., 2013), and GSK3 inhibition can lead to SMAD3 activation and fibrosis in cultured cardiac myocytes and fibroblasts (Hua et al., 2010; Lal et al., 2014). In the kidney, GSK3 inhibition has been associated with EMT in unilateral ureteral obstruction (UUO) in vivo and renal epithelial cells in vitro by increasing TGF-β1-induced β-catenin and Snail accumulation (Lan et al., 2014; Noh et al., 2012; Yoshino et al., 2007; Zhou et al., 2004). Moreover, in a transgenic mouse expressing constitutively active GSK3α and GSKβ, α-SMA levels did not increase following 3 days of UUO (Voelkl et al., 2013). The results of the current studies in an I/R model of AKI are consistent with a pro-fibrotic role for GSK3β by its involvement in TGF-β signaling in the kidney. We demonstrate that pSMAD3 expression colocalized with GSK3β in fibrotic kidney following I/R and systemic GSK3 inhibition significantly reduced expression of TGF-β1, pSMAD3 and PAI-1, a SMAD-regulated profibrotic gene. This suggests that TGF-β–SMAD3 signaling is active in vehicle-treated I/R kidneys and GSK3 inhibition suppresses it. Moreover, GSK3 inhibition using TDZD or SB216763 abolished TGF-β1-induced SMAD3 activation and α-SMA expression in cultured renal fibroblasts. Because TGF-β1 treatment also increased GSK3β expression and activity, GSK3β could play an essential role in TGF-β1-signaling-mediated fibroblast activation and development of fibrosis.

In addition to SMAD, the Wnt signaling pathway also mediates the effects of TGF-β1 (Akhmetshina et al., 2012; Zhou, 2011). Wnt signaling has been implicated in the pathogenesis of renal fibrosis based on the findings that expression of Wnt ligands is upregulated in fibrotic kidneys, and inhibition of Wnt signaling using DKK-1, sFRP4 or paricalcitol can reduce renal fibrosis in mice (DiRocco et al., 2013; Hao et al., 2011; He et al., 2009; Ren et al., 2013; Surendran et al., 2005). GSK3 is linked to canonical Wnt signaling by virtue of its ability to prevent cytoplasmic accumulation of β-catenin in the absence of Wnt ligands (Kaidanovich-Beilin and Woodgett, 2011). In the absence of Wnt ligands, GSK3β phosphorylates β-catenin, which prevents its cytoplasmic accumulation (Yost et al., 1996). In the presence of Wnt ligands, GSK3β is unable to phosphorylate β-catenin, leading to its accumulation and increased activity. Although the role of Wnt ligands in the development of renal fibrosis is clear, the role of β-catenin, an important component of canonical Wnt signaling, has been inconclusive. Renal β-catenin is increased in experimental models of renal fibrosis (He et al., 2009; Ren et al., 2013; Surendran et al., 2005) and its systemic inhibition can reduce fibrosis (Hao et al., 2011). However, although DKK-1, a Wnt antagonist significantly reduced renal β-catenin abundance (He et al., 2009), the anti-fibrotic effects of DKK-1 were found to be independent of β-catenin in UUO and I/R models of fibrosis (Ren et al., 2013). Moreover, gene deletion of β-catenin in tubular epithelium did not reduce renal fibrosis (Zhou et al., 2013). In the current studies, renal β-catenin abundance increased significantly in TDZD-treated mice, consistent with our previous studies (Howard et al., 2012). However, β-catenin expression in TDZD-treated mice was localized to tubules and, consistent with Zhou et al.'s observation (Zhou et al., 2013), increased renal tubular β-catenin levels did not result in increased α-SMA, ECM or fibrosis. Regardless of the role of β-catenin in the development of renal fibrosis, the involvement of GSK3 in fibroblast activation or renal fibrosis does not seem to be linked to β-catenin in the post-I/R kidney. This is further supported by the findings that both increased β-catenin (von Toerne et al., 2009) and increased GSK3β (Gong et al., 2008; Yan et al., 2012) occur in renal tubules of human chronic renal allograft nephropathy.

Injured tubules are known to recruit macrophages, secrete cytokines and chemokines, and generally induce fibrosis (Bonventre and Yang, 2011). Because GSK3β expression was observed in both renal tubular epithelial cells and interstitial fibroblasts, it cannot be excluded at this point that GSK3 inhibition could have led to complete and proper repair of the renal tubules after I/R and thereby resulted in reduced inflammation, TGF-β signaling and fibrosis. However, the in vitro and in vivo findings that (a) GSK3β is expressed in myofibroblasts, (b) GSK3β activity is crucial for TGF-β signaling and α-SMA expression, and (c) constitutively active GSK3β can increase α-SMA expression in vitro, suggest that GSK3β could play an important role in fibroblast differentiation and renal fibrosis.

In summary, our study is the first to demonstrate that GSK3 is a key pathogenic determinant in the development of renal fibrosis. The pro-fibrogenic role of GSK3 in the post I/R kidney could be coupled to TGF-β signaling, although additional studies are needed to address the mechanism. As such, the results show that pharmacological inhibition of GSK3, even after the detection of AKI in patients, could suppress fibroblast activation and development of renal fibrosis.

MATERIALS AND METHODS

Bilateral I/R surgery and experimental protocol

Bilateral I/R was carried out essentially as described earlier (Wei and Dong, 2012) on male C57/BL6J mice (Jackson Laboratory, Bar Harbor, MN) weighing approximately 25 g. Briefly, both renal pedicles were exposed by flank incisions and clamped using micro aneurysm clamps for 30 min under pentobarbital anesthesia [60 mg/kg BWt, intraperitoneal (IP)]. At the end of the ischemic period, the clamps were released for reperfusion.

Study groups were: (1) sham: mice underwent surgery to expose renal pedicle, without clamping; (2) vehicle-treated I/R: mice underwent surgery for I/R and received vehicle injection (10% DMSO) 1 h before clamping; (3) TDZD-Pre I/R: mice underwent surgery for I/R and received TDZD daily, starting 1 h before I/R; (4) TDZD-Post I/R: mice underwent surgery for I/R and received TDZD daily, starting 48 h after I/R. n=6 for each group.

TDZD (TDZD-8) was dissolved in 10% DMSO and administered by daily IP injection at a dose of 1 mg/kg BWt. All experiments were approved by the IACUC committee of University of Kansas Medical Center. Blood was collected from tail vein and plasma used to measure BUN using a QuantiChrom Urea Assay Kit from BioAssay Systems (Hayward, CA) following the manufacturer's instructions.

Quantitative real-time PCR (RT-PCR)

Total RNA was extracted using TRIzol (Sigma-Aldrich, MO) and first-strand cDNA synthesized using a reverse transcription system kit (Applied Biosystems, NY). RT-PCR was performed on an ABI PRISM 7000 sequence detection system (Applied Biosystems, Foster City, CA). Primer sequences are provided in supplementary data Table S1. The mRNA levels were calculated relative to β-actin levels for each sample.

In vitro studies

NRK-49F cells (ATCC, VA) were cultured in DMEM medium containing 5% fetal bovine serum, 0.5% penicillin and streptomycin. Cells were serum starved for 16 h followed by TGF-β1 (Sigma-Aldrich, MO) treatment for 48 h. Adenovirus, AdGSK3β-CA, carrying a serine-to-alanine substitution at Ser-9 in the NH2-terminal region of GSK3β was a gift from Dr Thomas Force (Haq et al., 2000). AdGSK3β-CA and control, AdGFP, have been described before (Rao et al., 2004). The recombinant viruses were propagated in HEK 293 cells, and high titer stocks (2×1010 particles/ml) were purified by CsCl density gradient centrifugation. For infection of NRK-49F cells, virus of 5 or 10 multiplicity of infection (MOI) was added to each culture dish.

Western blot analysis

Kidney tissues were lysed in RIPA buffer and loaded onto SDS-PAGE gels, transferred to nitrocellulose membranes and blocked with 5% milk in TBST. Membranes were probed with primary antibody followed by TBST washes and horseradish peroxidase secondary antibody application. Secondary antibodies were purchased from Dako (CA).

Antibodies used

For western blot and immunostaining of tissue sections, antibodies for GSK3β, pGSK3β, β-catenin, fibronectin, α-SMA (Cell Signaling Technology, Inc., MA), collagen I (MD Bioproducts, MN), GAPDH, pERK and ERK (Santa Cruz Biotechnology, Inc., TX), β-actin (Sigma-Aldrich, MO) were used. Secondary antibodies were purchased from Dako (CA). Antibodies used only for immunohistochemistry (IHC)/IF staining were anti-α-SMA, F4/80 (Serotec, NC), PCNA (Dako, CA), DBA and LTA (Vector Laboratories, CA), BrdU (Cell Signaling Technology, Inc., MA), and pSMAD3 (Rockland, PA).

Histology, immunohistochemistry and immunofluorescence

Kidney sections were fixed in 4% paraformaldehyde and blocked in paraffin. Picro sirius red staining (Polysciences, PA) was carried out and fibrillar collagen was visualized under polarized light. Masson's trichrome staining was carried out using staining kit (Polysciences, PA). For both IHC and IF, paraffin sections were de-paraffinised, washed in PBS containing 0.1% Tween 20 (PBST) and blocked in 10% normal goat serum.

Primary antibodies were applied to sections and incubated at 4°C overnight. For IHC, slides were blocked with Avidin/Biotin (Invitrogen, NY), and then biotinylated goat anti-rabbit IgG or anti-mouse IgG (Invitrogen, NY) secondary antibodies were applied, followed by incubation with Streptavidin HRP conjugate (Invitrogen, NY). Finally, slides were developed with DAB (Vector Laboratories, CA) and counterstained with Harris Haematoxylin, dehydrated, and mounted with Permount (Fisher Scientific). For IF, after incubation with primary antibody, goat anti-rabbit IgG Alexa-Fluor-488, goat anti-mouse IgG Texas red, or goat anti-chicken IgG Alexa-Fluor-555 secondary antibodies were applied, and, following incubation, washed, stained with DAPI and mounted with Flour-G (Invitrogen, NY). All images were captured using a Nikon 80i microscope in KUMC imaging center.

Statistics

Values are expressed as mean±standard error for all bar charts, except for band density measurements of western blots, which is expressed as mean±standard deviation. Data was analyzed using Graphpad Prism software (Version 5.0d). Two-tailed unpaired t-test with Welch's correction and F-test to compare variances and One-Way Analysis of Variance followed by Tukey's multiple comparison test and Bartlett's test for equal variance were used. A probability level of 0.05 (P≤0.05) was considered significant.

Acknowledgements

We thank the UAB-UCSD O'Brien Center (P30-DK079337) for providing training in the acute kidney injury model.

Footnotes

  • ↵* These authors contributed equally to this work

  • Competing interests

    The authors declare no competing or financial interests.

  • Author contributions

    R.R. conceived the project and designed the experiments; S.P.S. and S.T. performed the experiments; S.W. performed mouse surgeries; T.A.F. carried out blinded renal pathology scoring and R.R., S.P.S. and S.T. analyzed and interpreted the data. R.R. wrote the paper; R.C.H. provided expert consultation and edited the paper.

  • Funding

    These studies were supported by R01 DK-083525 grant to R.R. and by PKD foundation grant (189G14a) to T.A.F.

  • Supplementary material

    Supplementary material available online at http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.020511/-/DC1

  • Received February 23, 2015.
  • Accepted May 26, 2015.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

References

  1. ↵
    1. Akhmetshina, A.,
    2. Palumbo, K.,
    3. Dees, C.,
    4. Bergmann, C.,
    5. Venalis, P.,
    6. Zerr, P.,
    7. Horn, A.,
    8. Kireva, T.,
    9. Beyer, C.,
    10. Zwerina, J. et al.
    (2012). Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat. Commun. 3, 735. doi:10.1038/ncomms1734
    OpenUrlCrossRefPubMed
  2. ↵
    1. Bahammam, M.,
    2. Black, S. A., Jr.,
    3. Sume, S. S.,
    4. Assaggaf, M. A.,
    5. Faibish, M. and
    6. Trackman, P. C.
    (2013). Requirement for active glycogen synthase kinase-3beta in TGF-beta1 upregulation of connective tissue growth factor (CCN2/CTGF) levels in human gingival fibroblasts. Am. J. Physiol. Cell Physiol. 305, C581-C590. doi:10.1152/ajpcell.00032.2013
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Bao, H.,
    2. Ge, Y.,
    3. Zhuang, S.,
    4. Dworkin, L. D.,
    5. Liu, Z. and
    6. Gong, R.
    (2012). Inhibition of glycogen synthase kinase-3beta prevents NSAID-induced acute kidney injury. Kidney Int. 81, 662-673. doi:10.1038/ki.2011.443
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Bao, H.,
    2. Ge, Y.,
    3. Wang, Z.,
    4. Zhuang, S.,
    5. Dworkin, L.,
    6. Peng, A. and
    7. Gong, R.
    (2014). Delayed administration of a single dose of lithium promotes recovery from AKI. J. Am. Soc. Nephrol. 25, 488-500. doi:10.1681/ASN.2013040350
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Beurel, E.,
    2. Grieco, S. F. and
    3. Jope, R. S.
    (2015). Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol. Ther. 148, 114-131. doi:10.1016/j.pharmthera.2014.11.016
    OpenUrlCrossRefPubMed
  6. ↵
    1. Bonventre, J. V. and
    2. Yang, L.
    (2011). Cellular pathophysiology of ischemic acute kidney injury. J. Clin. Invest. 121, 4210-4221. doi:10.1172/JCI45161
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Choi, S.-I.,
    2. Kim, B.-Y.,
    3. Dadakhujaev, S.,
    4. Jester, J. V.,
    5. Ryu, H.,
    6. Kim, T.-I. and
    7. Kim, E. K.
    (2011). Inhibition of TGFBIp expression by lithium: implications for TGFBI-linked corneal dystrophy therapy. Invest. Ophthalmol. Vis. Sci. 52, 3293-3300. doi:10.1167/iovs.10-6405
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Chuang, P. Y.,
    2. Menon, M. C. and
    3. He, J. C.
    (2013). Molecular targets for treatment of kidney fibrosis. J. Mol. Med. 91, 549-559. doi:10.1007/s00109-012-0983-z
    OpenUrlCrossRefPubMed
  9. ↵
    1. Correa-Costa, M.,
    2. Braga, T. T.,
    3. Felizardo, R. J. F.,
    4. Andrade-Oliveira, V.,
    5. Perez, K. R.,
    6. Cuccovia, I. M.,
    7. Hiyane, M. I.,
    8. da Silva, J. S. and
    9. Câmara, N. O. S.
    (2014). Macrophage trafficking as key mediator of adenine-induced kidney injury. Mediators Inflamm. 2014, 291024. doi:10.1155/2014/291024
    OpenUrlCrossRefPubMed
  10. ↵
    1. Ding, Q.,
    2. Xia, W.,
    3. Liu, J.-C.,
    4. Yang, J.-Y.,
    5. Lee, D.-F.,
    6. Xia, J.,
    7. Bartholomeusz, G.,
    8. Li, Y.,
    9. Pan, Y.,
    10. Li, Z. et al.
    (2005). Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol. Cell 19, 159-170. doi:10.1016/j.molcel.2005.06.009
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. DiRocco, D. P.,
    2. Kobayashi, A.,
    3. Taketo, M. M.,
    4. McMahon, A. P. and
    5. Humphreys, B. D.
    (2013). Wnt4/beta-catenin signaling in medullary kidney myofibroblasts. J. Am. Soc. Nephrol. 24, 1399-1412. doi:10.1681/ASN.2012050512
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Dugo, L.,
    2. Collin, M. and
    3. Thiemermann, C.
    (2007). Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation. Shock 27, 113-123. doi:10.1097/01.shk.0000238059.23837.68
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Farris, A. B. and
    2. Colvin, R. B.
    (2012). Renal interstitial fibrosis: mechanisms and evaluation. Curr. Opin. Nephrol. Hypertens. 21, 289-300. doi:10.1097/MNH.0b013e3283521cfa
    OpenUrlCrossRefPubMed
  14. ↵
    1. Furuichi, K.,
    2. Kaneko, S. and
    3. Wada, T.
    (2009). Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease. Clin. Exp. Nephrol. 13, 9-14. doi:10.1007/s10157-008-0119-5
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Gong, R.,
    2. Ge, Y.,
    3. Chen, S.,
    4. Liang, E.,
    5. Esparza, A.,
    6. Sabo, E.,
    7. Yango, A.,
    8. Gohh, R.,
    9. Rifai, A. and
    10. Dworkin, L. D.
    (2008). Glycogen synthase kinase 3beta: a novel marker and modulator of inflammatory injury in chronic renal allograft disease. Am. J. Transplant. 8, 1852-1863. doi:10.1111/j.1600-6143.2008.02319.x
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Grande, M. T. and
    2. Lopez-Novoa, J. M.
    (2009). Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat. Rev. Nephrol. 5, 319-328. doi:10.1038/nrneph.2009.74
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Hao, S.,
    2. He, W.,
    3. Li, Y.,
    4. Ding, H.,
    5. Hou, Y.,
    6. Nie, J.,
    7. Hou, F. F.,
    8. Kahn, M. and
    9. Liu, Y.
    (2011). Targeted inhibition of beta-catenin/CBP signaling ameliorates renal interstitial fibrosis. J. Am. Soc. Nephrol. 22, 1642-1653. doi:10.1681/ASN.2010101079
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Haq, S.,
    2. Choukroun, G.,
    3. Kang, Z. B.,
    4. Ranu, H.,
    5. Matsui, T.,
    6. Rosenzweig, A.,
    7. Molkentin, J. D.,
    8. Alessandrini, A.,
    9. Woodgett, J.,
    10. Hajjar, R. et al.
    (2000). Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J. Cell Biol. 151, 117-130. doi:10.1083/jcb.151.1.117
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. He, W.,
    2. Dai, C.,
    3. Li, Y.,
    4. Zeng, G.,
    5. Monga, S. P. and
    6. Liu, Y.
    (2009). Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J. Am. Soc. Nephrol. 20, 765-776. doi:10.1681/ASN.2008060566
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Ho, C.,
    2. Lee, P. H.,
    3. Hsu, Y. C.,
    4. Wang, F. S.,
    5. Huang, Y. T. and
    6. Lin, C. L.
    (2012). Sustained Wnt/beta-catenin signaling rescues high glucose induction of transforming growth factor-beta1-mediated renal fibrosis. Am. J. Med. Sci. 344, 374-382.
    OpenUrlPubMed
  21. ↵
    1. Howard, C.,
    2. Tao, S.,
    3. Yang, H.-C.,
    4. Fogo, A. B.,
    5. Woodgett, J. R.,
    6. Harris, R. C. and
    7. Rao, R.
    (2012). Specific deletion of glycogen synthase kinase-3beta in the renal proximal tubule protects against acute nephrotoxic injury in mice. Kidney Int. 82, 1000-1009. doi:10.1038/ki.2012.239
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Hua, F.,
    2. Zhou, J.,
    3. Liu, J.,
    4. Zhu, C.,
    5. Cui, B.,
    6. Lin, H.,
    7. Liu, Y.,
    8. Jin, W.,
    9. Yang, H. and
    10. Hu, Z.
    (2010). Glycogen synthase kinase-3beta negatively regulates TGF-beta1 and Angiotensin II-mediated cellular activity through interaction with Smad3. Eur. J. Pharmacol. 644, 17-23. doi:10.1016/j.ejphar.2010.06.042
    OpenUrlCrossRefPubMed
  23. ↵
    1. Jang, Y.-H.,
    2. Shin, H.-S.,
    3. Sun Choi, H.,
    4. Ryu, E.-S.,
    5. Jin Kim, M.,
    6. Ki Min, S.,
    7. Lee, J.-H.,
    8. Kook Lee, H.,
    9. Kim, K.-H. and
    10. Kang, D.-H.
    (2013). Effects of dexamethasone on the TGF-beta1-induced epithelial-to-mesenchymal transition in human peritoneal mesothelial cells. Lab. Invest. 93, 194-206. doi:10.1038/labinvest.2012.166
    OpenUrlCrossRefPubMed
  24. ↵
    1. Jang, H.-S.,
    2. Kim, J. I.,
    3. Han, S. J. and
    4. Park, K. M.
    (2014). Recruitment and subsequent proliferation of bone marrow-derived cells in the postischemic kidney are important to the progression of fibrosis. Am. J. Physiol. Renal Physiol. 306, F1451-F1461. doi:10.1152/ajprenal.00017.2014
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Kaidanovich-Beilin, O. and
    2. Woodgett, J. R.
    (2011). GSK-3: functional insights from cell biology and animal models. Front. Mol. Neurosci. 4, 40. doi:10.3389/fnmol.2011.00040
    OpenUrlCrossRefPubMed
  26. ↵
    1. Kalluri, R. and
    2. Zeisberg, M.
    (2006). Fibroblasts in cancer. Nat. Rev. Cancer 6, 392-401. doi:10.1038/nrc1877
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Kendall, R. T. and
    2. Feghali-Bostwick, C. A.
    (2014). Fibroblasts in fibrosis: novel roles and mediators. Front. Pharmacol. 5, 123. doi:10.3389/fphar.2014.00123
    OpenUrlCrossRefPubMed
  28. ↵
    1. Kim, J. and
    2. Padanilam, B. J.
    (2015). Renal denervation prevents long-term sequelae of ischemic renal injury. Kidney Int. 87, 350-358. doi:10.1038/ki.2014.300
    OpenUrlCrossRefPubMed
  29. ↵
    1. Kramann, R.,
    2. DiRocco, D. P. and
    3. Humphreys, B. D.
    (2013). Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease. J. Pathol. 231, 273-289. doi:10.1002/path.4253
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Lal, H.,
    2. Ahmad, F.,
    3. Zhou, J.,
    4. Yu, J. E.,
    5. Vagnozzi, R. J.,
    6. Guo, Y.,
    7. Yu, D.,
    8. Tsai, E. J.,
    9. Woodgett, J.,
    10. Gao, E. et al.
    (2014). Cardiac fibroblast glycogen synthase kinase-3beta regulates ventricular remodeling and dysfunction in ischemic heart. Circulation 130, 419-430. doi:10.1161/CIRCULATIONAHA.113.008364
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Lan, A.,
    2. Qi, Y. and
    3. Du, J.
    (2014). Akt2 mediates TGF-beta1-induced epithelial to mesenchymal transition by deactivating GSK3beta/snail signaling pathway in renal tubular epithelial cells. Cell Physiol. Biochem. 34, 368-382. doi:10.1159/000363006
    OpenUrlCrossRefPubMed
  32. ↵
    1. LeBleu, V. S.,
    2. Taduri, G.,
    3. O'Connell, J.,
    4. Teng, Y.,
    5. Cooke, V. G.,
    6. Woda, C.,
    7. Sugimoto, H. and
    8. Kalluri, R.
    (2013). Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 19, 1047-1053. doi:10.1038/nm.3218
    OpenUrlCrossRefPubMed
  33. ↵
    1. Liu, J.,
    2. Wang, Y.,
    3. Pan, Q.,
    4. Su, Y.,
    5. Zhang, Z.,
    6. Han, J.,
    7. Zhu, X.,
    8. Tang, C. and
    9. Hu, D.
    (2012). Wnt/beta-catenin pathway forms a negative feedback loop during TGF-beta1 induced human normal skin fibroblast-to-myofibroblast transition. J. Dermatol. Sci. 65, 38-49. doi:10.1016/j.jdermsci.2011.09.012
    OpenUrlCrossRefPubMed
  34. ↵
    1. Ma, L. J. and
    2. Fogo, A. B.
    (2009). PAI-1 and kidney fibrosis. Front. Biosci. 14, 2028-2041. doi:10.2741/3361
    OpenUrlCrossRefPubMed
  35. ↵
    1. Martin, M.,
    2. Rehani, K.,
    3. Jope, R. S. and
    4. Michalek, S. M.
    (2005). Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6, 777-784. doi:10.1038/ni1221
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Martinez, A.,
    2. Alonso, M.,
    3. Castro, A.,
    4. Pérez, C. and
    5. Moreno, F. J.
    (2002). First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 45, 1292-1299. doi:10.1021/jm011020u
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Noh, H.,
    2. Kim, H. J.,
    3. Yu, M. R.,
    4. Kim, W.-Y.,
    5. Kim, J.,
    6. Ryu, J. H.,
    7. Kwon, S. H.,
    8. Jeon, J. S.,
    9. Han, D. C. and
    10. Ziyadeh, F.
    (2012). Heat shock protein 90 inhibitor attenuates renal fibrosis through degradation of transforming growth factor-beta type II receptor. Lab. Invest. 92, 1583-1596. doi:10.1038/labinvest.2012.127
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Nørregaard, R.,
    2. Tao, S.,
    3. Nilsson, L.,
    4. Woodgett, J. R.,
    5. Kakade, V.,
    6. Yu, A. S. L.,
    7. Howard, C. and
    8. Rao, R.
    (2015). Glycogen synthase kinase 3alpha regulates urine concentrating mechanism in mice. Am. J. Physiol. Renal Physiol. 308, F650-F660. doi:10.1152/ajprenal.00516.2014
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Plotnikov, E. Y.,
    2. Grebenchikov, O. A.,
    3. Babenko, V. A.,
    4. Pevzner, I. B.,
    5. Zorova, L. D.,
    6. Likhvantsev, V. V. and
    7. Zorov, D. B.
    (2013). Nephroprotective effect of GSK-3beta inhibition by lithium ions and delta-opioid receptor agonist dalargin on gentamicin-induced nephrotoxicity. Toxicol. Lett. 220, 303-308. doi:10.1016/j.toxlet.2013.04.023
    OpenUrlCrossRefPubMed
  40. ↵
    1. Rao, R.,
    2. Hao, C.-M. and
    3. Breyer, M. D.
    (2004). Hypertonic stress activates glycogen synthase kinase 3beta-mediated apoptosis of renal medullary interstitial cells, suppressing an NFkappaB-driven cyclooxygenase-2-dependent survival pathway. J. Biol. Chem. 279, 3949-3955. doi:10.1074/jbc.M309325200
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Ren, S.,
    2. Johnson, B. G.,
    3. Kida, Y.,
    4. Ip, C.,
    5. Davidson, K. C.,
    6. Lin, S.-L.,
    7. Kobayashi, A.,
    8. Lang, R. A.,
    9. Hadjantonakis, A.-K.,
    10. Moon, R. T. et al.
    (2013). LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc. Natl. Acad. Sci. USA 110, 1440-1445. doi:10.1073/pnas.1211179110
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Samarakoon, R.,
    2. Overstreet, J. M.,
    3. Higgins, S. P. and
    4. Higgins, P. J.
    (2012). TGF-beta1→SMAD/p53/USF2→PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis. Cell Tissue Res. 347, 117-128. doi:10.1007/s00441-011-1181-y
    OpenUrlCrossRefPubMedWeb of Science
  43. ↵
    1. Strutz, F. and
    2. Zeisberg, M.
    (2006). Renal fibroblasts and myofibroblasts in chronic kidney disease. J. Am. Soc. Nephrol. 17, 2992-2998. doi:10.1681/ASN.2006050420
    OpenUrlFREE Full Text
  44. ↵
    1. Surendran, K.,
    2. Schiavi, S. and
    3. Hruska, K. A.
    (2005). Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J. Am. Soc. Nephrol. 16, 2373-2384. doi:10.1681/ASN.2004110949
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Tao, S.,
    2. Kakade, V. R.,
    3. Woodgett, J. R.,
    4. Pandey, P.,
    5. Suderman, E. D.,
    6. Rajagopal, M. and
    7. Rao, R.
    (2015). Glycogen synthase kinase-3beta promotes cyst expansion in polycystic kidney disease. Kidney Int. 87, 1164-1175. doi:10.1038/ki.2014.427
    OpenUrlCrossRefPubMed
  46. ↵
    1. Venkatachalam, M. A.,
    2. Griffin, K. A.,
    3. Lan, R.,
    4. Geng, H.,
    5. Saikumar, P. and
    6. Bidani, A. K.
    (2010). Acute kidney injury: a springboard for progression in chronic kidney disease. Am. J. Physiol. Renal Physiol. 298, F1078-F1094. doi:10.1152/ajprenal.00017.2010
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Voelkl, J.,
    2. Mia, S.,
    3. Meissner, A.,
    4. Ahmed, M. S.,
    5. Feger, M.,
    6. Elvira, B.,
    7. Walker, B.,
    8. Alessi, D. R.,
    9. Alesutan, I. and
    10. Lang, F.
    (2013). PKB/SGK-resistant GSK-3 signaling following unilateral ureteral obstruction. Kidney Blood Press. Res. 38, 156-164. doi:10.1159/000355763
    OpenUrlCrossRefPubMed
  48. ↵
    1. von Toerne, C.,
    2. Schmidt, C.,
    3. Adams, J.,
    4. Kiss, E.,
    5. Bedke, J.,
    6. Porubsky, S.,
    7. Gretz, N.,
    8. Lindenmeyer, M. T.,
    9. Cohen, C. D.,
    10. Gröne, H.-J. et al.
    (2009). Wnt pathway regulation in chronic renal allograft damage. Am. J. Transplant. 9, 2223-2239. doi:10.1111/j.1600-6143.2009.02762.x
    OpenUrlCrossRefPubMedWeb of Science
  49. ↵
    1. Wang, Y.,
    2. Huang, W. C.,
    3. Wang, C. Y.,
    4. Tsai, C. C.,
    5. Chen, C. L.,
    6. Chang, Y. T.,
    7. Kai, J. I. and
    8. Lin, C. F.
    (2009). Inhibiting glycogen synthase kinase-3 reduces endotoxaemic acute renal failure by down-regulating inflammation and renal cell apoptosis. Br. J. Pharmacol. 157, 1004-1013. doi:10.1111/j.1476-5381.2009.00284.x
    OpenUrlCrossRefPubMedWeb of Science
  50. ↵
    1. Wang, Z.,
    2. Havasi, A.,
    3. Gall, J.,
    4. Bonegio, R.,
    5. Li, Z.,
    6. Mao, H.,
    7. Schwartz, J. H. and
    8. Borkan, S. C.
    (2010). GSK3β promotes apoptosis after renal ischemic injury. J. Am. Soc. Nephrol. 21, 284-294. doi:10.1681/ASN.2009080828
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Wang, H.,
    2. Brown, J. and
    3. Martin, M.
    (2011). Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. Cytokine 53, 130-140. doi:10.1016/j.cyto.2010.10.009
    OpenUrlCrossRefPubMedWeb of Science
  52. ↵
    1. Wei, Q. and
    2. Dong, Z.
    (2012). Mouse model of ischemic acute kidney injury: technical notes and tricks. Am. J. Physiol. Renal Physiol. 303, F1487-F1494. doi:10.1152/ajprenal.00352.2012
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Yan, Q.,
    2. Wang, B.,
    3. Sui, W.,
    4. Zou, G.,
    5. Chen, H.,
    6. Xie, S. and
    7. Zou, H.
    (2012). Expression of GSK-3beta in renal allograft tissue and its significance in pathogenesis of chronic allograft dysfunction. Diagn. Pathol. 7, 5. doi:10.1186/1746-1596-7-5
    OpenUrlCrossRefPubMed
  54. ↵
    1. Yang, L.,
    2. Besschetnova, T. Y.,
    3. Brooks, C. R.,
    4. Shah, J. V. and
    5. Bonventre, J. V.
    (2010). Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat. Med. 16, 535-543. doi:10.1038/nm.2144
    OpenUrlCrossRefPubMedWeb of Science
  55. ↵
    1. Yoshino, J.,
    2. Monkawa, T.,
    3. Tsuji, M.,
    4. Inukai, M.,
    5. Itoh, H. and
    6. Hayashi, M.
    (2007). Snail1 is involved in the renal epithelial-mesenchymal transition. Biochem. Biophys. Res. Commun. 362, 63-68. doi:10.1016/j.bbrc.2007.07.146
    OpenUrlCrossRefPubMedWeb of Science
  56. ↵
    1. Yost, C.,
    2. Torres, M.,
    3. Miller, J. R.,
    4. Huang, E.,
    5. Kimelman, D. and
    6. Moon, R. T.
    (1996). The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 10, 1443-1454. doi:10.1101/gad.10.12.1443
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Zarjou, A. and
    2. Agarwal, A.
    (2012). Heme oxygenase-1 as a target for TGF-beta in kidney disease. Semin. Nephrol. 32, 277-286. doi:10.1016/j.semnephrol.2012.04.007
    OpenUrlCrossRefPubMed
  58. ↵
    1. Zhang, M.,
    2. Lee, C.-H.,
    3. Luo, D. D.,
    4. Krupa, A.,
    5. Fraser, D. and
    6. Phillips, A.
    (2007). Polarity of response to transforming growth factor-beta1 in proximal tubular epithelial cells is regulated by beta-catenin. J. Biol. Chem. 282, 28639-28647. doi:10.1074/jbc.M700594200
    OpenUrlAbstract/FREE Full Text
  59. ↵
    1. Zhou, S.
    (2011). TGF-beta regulates beta-catenin signaling and osteoblast differentiation in human mesenchymal stem cells. J. Cell Biochem. 112, 1651-1660. doi:10.1002/jcb.23079
    OpenUrlCrossRefPubMed
  60. ↵
    1. Zhou, B. P.,
    2. Deng, J.,
    3. Xia, W.,
    4. Xu, J.,
    5. Li, Y. M.,
    6. Gunduz, M. and
    7. Hung, M.-C.
    (2004). Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell Biol. 6, 931-940. doi:10.1038/ncb1173
    OpenUrlCrossRefPubMedWeb of Science
  61. ↵
    1. Zhou, D.,
    2. Tan, R. J.,
    3. Zhou, L.,
    4. Li, Y. and
    5. Liu, Y.
    (2013). Kidney tubular beta-catenin signaling controls interstitial fibroblast fate via epithelial-mesenchymal communication. Sci. Rep. 3, 1878. doi:10.1038/srep01878
    OpenUrlCrossRefPubMed
  62. ↵
    1. Zhou, D.,
    2. Li, Y.,
    3. Zhou, L.,
    4. Tan, R. J.,
    5. Xiao, L.,
    6. Liang, M.,
    7. Hou, F. F. and
    8. Liu, Y.
    (2014). Sonic hedgehog is a novel tubule-derived growth factor for interstitial fibroblasts after kidney injury. J. Am. Soc. Nephrol. 25, 2187-2200. doi:10.1681/ASN.2013080893
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top

RSSRSS

Keywords

 Download PDF

Email
RESEARCH ARTICLE
Glycogen synthase kinase-3 inhibition attenuates fibroblast activation and development of fibrosis following renal ischemia-reperfusion in mice
Shailendra P. Singh, Shixin Tao, Timothy A. Fields, Sydney Webb, Raymond C. Harris, Reena Rao
Disease Models & Mechanisms 2015 8: 931-940; doi: 10.1242/dmm.020511
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Alerts

Article navigation

Other journals from The Company of Biologists

Advertisement

DMM and COVID-19

We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.

Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.

The twin pillars of Disease Models & Mechanisms

In her first Editorial as Editor-in-Chief, Liz Patton sets out her vision and priorities for DMM focusing on four thematic challenges: mechanisms of disease, innovative technologies, disease progression through time and therapy.

Extended deadline - The RAS Pathway: Diseases, Therapeutics and Beyond

Our upcoming special issue is welcoming submissions until 3 May 2021. Guest-edited by Donita Brady (Perelman School of Medicine at the University of Pennsylvania, USA) and Arvin Dar (Icahn School of Medicine at Mount Sinai, USA), the issue will focus on the targeting the RAS pathway.

Find out more about the issue and how to submit your manuscript.

Perspective - Modelling the developmental origins of paediatric cancer to improve patient outcomes

James Amatruda authors our first Perspective, discussing some of the key challenges in paediatric cancer from his perspective as a physician-scientist.

A muscle growth-promoting treatment based on the attenuation of activin/myostatin signalling results in long-term testicular abnormalities

In this issue’s Editor’s choice, Ketan Patel and colleagues describe how even brief exposure to muscle-growth-promoting treatments exerts a long-term detrimental effect on the testes, and test promising therapeutics to mitigate this side-effect.